Company

Selexys Pharmaceuticals Corporation

Selexys Pharmaceuticals develops investigational treatments for blood disorders, including sickle cell disease.

About

Selexys Pharmaceuticals develops investigational therapies for hematological conditions, with a focus on sickle cell disease. The company is based in Oklahoma City, US. In November 2016, it raised USD 8.740 mn; that month, Novartis International AG announced plans to acquire it for up to USD 665 million, including acquisition and milestone payments.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in